Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 482

    1.

    A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.

    Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, Hudis C, Roberge D, Norton L, Bégin LR, Offit K, Foulkes WD.

    Breast Cancer Res. 2004;6(1):R8-R17. Epub 2003 Oct 24.

    PMID:
    14680495
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations.

    Robson M, Levin D, Federici M, Satagopan J, Bogolminy F, Heerdt A, Borgen P, McCormick B, Hudis C, Norton L, Boyd J, Offit K.

    J Natl Cancer Inst. 1999 Dec 15;91(24):2112-7.

    PMID:
    10601383
    [PubMed - indexed for MEDLINE]
    Free Article
    3.

    Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment.

    Chappuis PO, Donato E, Goffin JR, Wong N, Bégin LR, Kapusta LR, Brunet JS, Porter P, Foulkes WD.

    Ann Oncol. 2005 May;16(5):735-42. Epub 2005 Mar 31.

    PMID:
    15802279
    [PubMed - indexed for MEDLINE]
    Free Article
    4.

    Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.

    Goffin JR, Chappuis PO, Bégin LR, Wong N, Brunet JS, Hamel N, Paradis AJ, Boyd J, Foulkes WD.

    Cancer. 2003 Feb 1;97(3):527-36.

    PMID:
    12548593
    [PubMed - indexed for MEDLINE]
    Free Article
    5.

    Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome.

    Foulkes WD, Chappuis PO, Wong N, Brunet JS, Vesprini D, Rozen F, Yuan ZQ, Pollak MN, Kuperstein G, Narod SA, Bégin LR.

    Ann Oncol. 2000 Mar;11(3):307-13.

    PMID:
    10811497
    [PubMed - indexed for MEDLINE]
    Free Article
    6.

    Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer.

    Chappuis PO, Kapusta L, Bégin LR, Wong N, Brunet JS, Narod SA, Slingerland J, Foulkes WD.

    J Clin Oncol. 2000 Dec 15;18(24):4045-52.

    PMID:
    11118465
    [PubMed - indexed for MEDLINE]
    7.

    Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

    Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K.

    Clin Cancer Res. 2002 Dec;8(12):3776-81.

    PMID:
    12473589
    [PubMed - indexed for MEDLINE]
    Free Article
    8.

    Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer.

    Hodgson SV, Heap E, Cameron J, Ellis D, Mathew CG, Eeles RA, Solomon E, Lewis CM.

    J Med Genet. 1999 May;36(5):369-73.

    PMID:
    10353781
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    9.

    Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.

    Wolf I, Laitman Y, Rubinek T, Abramovitz L, Novikov I, Beeri R, Kuro-O M, Koeffler HP, Catane R, Freedman LS, Levy-Lahad E, Karlan BY, Friedman E, Kaufman B.

    Oncogene. 2010 Jan 7;29(1):26-33. Epub 2009 Oct 5.

    PMID:
    19802015
    [PubMed - indexed for MEDLINE]
    10.

    Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.

    Kirova YM, Stoppa-Lyonnet D, Savignoni A, Sigal-Zafrani B, Fabre N, Fourquet A; for the Institut Curie Breast Cancer Study Group.

    Eur J Cancer. 2005 Oct;41(15):2304-11. Epub 2005 Sep 1.

    PMID:
    16140006
    [PubMed - indexed for MEDLINE]
    11.

    A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers.

    Levy-Lahad E, Lahad A, Eisenberg S, Dagan E, Paperna T, Kasinetz L, Catane R, Kaufman B, Beller U, Renbaum P, Gershoni-Baruch R.

    Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3232-6.

    PMID:
    11248061
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    12.

    Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status.

    Haffty BG, Harrold E, Khan AJ, Pathare P, Smith TE, Turner BC, Glazer PM, Ward B, Carter D, Matloff E, Bale AE, Alvarez-Franco M.

    Lancet. 2002 Apr 27;359(9316):1471-7.

    PMID:
    11988246
    [PubMed - indexed for MEDLINE]
    13.

    Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.

    Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS, Narod SA.

    N Engl J Med. 2007 Jul 12;357(2):115-23.

    PMID:
    17625123
    [PubMed - indexed for MEDLINE]
    Free Article
    14.

    Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.

    McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, Lynch H, Karlan B, Fishman D, Rosen B, Neuhausen SL, Offit K, Kauff N, Domchek S, Tung N, Friedman E, Foulkes W, Sun P, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.

    Lancet Oncol. 2007 Jan;8(1):26-34.

    PMID:
    17196508
    [PubMed - indexed for MEDLINE]
    15.

    The 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers.

    Gal I, Gershoni Baruch R, Haber D, Dagan E, Eisenberg-Barzilai S, Zidan J, Friedman E.

    Fam Cancer. 2004;3(1):11-4.

    PMID:
    15131400
    [PubMed - indexed for MEDLINE]
    16.

    Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.

    Hamel N, Kotar K, Foulkes WD.

    BMC Med Genet. 2003 Aug 11;4:7.

    PMID:
    12911837
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    17.

    Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.

    Lee JS, Wacholder S, Struewing JP, McAdams M, Pee D, Brody LC, Tucker MA, Hartge P.

    J Natl Cancer Inst. 1999 Feb 3;91(3):259-63.

    PMID:
    10037104
    [PubMed - indexed for MEDLINE]
    Free Article
    18.

    Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.

    Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC.

    J Clin Oncol. 2002 Mar 15;20(6):1480-90.

    PMID:
    11896095
    [PubMed - indexed for MEDLINE]
    19.

    Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999.

    Chodick G, Struewing JP, Ron E, Rutter JL, Iscovich J.

    Eur J Med Genet. 2008 Mar-Apr;51(2):141-7. Epub 2007 Nov 22.

    PMID:
    18158280
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    20.

    An evaluation of BRCA1 and BRCA2 founder mutations penetrance estimates for breast cancer among Ashkenazi Jewish women.

    McClain MR, Nathanson KL, Palomaki GE, Haddow JE.

    Genet Med. 2005 Jan;7(1):34-9.

    PMID:
    15654226
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk